A detailed history of Nuveen, LLC transactions in Intellia Therapeutics, Inc. stock. As of the latest transaction made, Nuveen, LLC holds 232,732 shares of NTLA stock, worth $2.02 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
232,732
Previous 237,441 1.98%
Holding current value
$2.02 Million
Previous $2.23 Million 80.47%
% of portfolio
0.0%
Previous 0.0%

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2025

Nov 12, 2025

SELL
$9.88 - $17.76 $46,524 - $83,631
-4,709 Reduced 1.98%
232,732 $4.02 Million
Q2 2025

Aug 12, 2025

SELL
$6.28 - $9.67 $218,895 - $337,057
-34,856 Reduced 12.8%
237,441 $2.23 Million
Q1 2025

May 12, 2025

BUY
$7.11 - $12.8 $1.94 Million - $3.49 Million
272,297 New
272,297 $1.94 Million

Others Institutions Holding NTLA

About Intellia Therapeutics, Inc.


  • Ticker NTLA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 76,011,800
  • Market Cap $661M
  • Description
  • Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemoph...
More about NTLA
Track This Portfolio

Track Nuveen, LLC Portfolio

Follow Nuveen, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Nuveen, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Nuveen, LLC with notifications on news.